214 related articles for article (PubMed ID: 21835849)
1. Cancer targeting gene-viro-therapy specific for liver cancer by α-fetoprotein-controlled oncolytic adenovirus expression of SOCS3 and IL-24.
Cao X; Wei R; Liu X; Zeng Y; Huang H; Ding M; Zhang K; Liu XY
Acta Biochim Biophys Sin (Shanghai); 2011 Oct; 43(10):813-21. PubMed ID: 21835849
[TBL] [Abstract][Full Text] [Related]
2. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
3. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
[TBL] [Abstract][Full Text] [Related]
4. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
[TBL] [Abstract][Full Text] [Related]
5. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
[TBL] [Abstract][Full Text] [Related]
6. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
7. Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma.
Cui Q; Jiang W; Wang Y; Lv C; Luo J; Zhang W; Lin F; Yin Y; Cai R; Wei P; Qian C
Hepatology; 2008 Jan; 47(1):105-12. PubMed ID: 17935223
[TBL] [Abstract][Full Text] [Related]
8. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene.
Ding M; Cao X; Xu HN; Fan JK; Huang HL; Yang DQ; Li YH; Wang J; Li R; Liu XY
PLoS One; 2012; 7(4):e35153. PubMed ID: 22509396
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
12. A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect.
Liu XR; Cai Y; Cao X; Wei RC; Li HL; Zhou XM; Zhang KJ; Wu S; Qian QJ; Cheng B; Huang K; Liu XY
J Cell Mol Med; 2012 Jun; 16(6):1298-309. PubMed ID: 21794078
[TBL] [Abstract][Full Text] [Related]
13. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
14. Targeting gene-virus-mediated manganese superoxide dismutase effectively suppresses tumor growth in hepatocellular carcinoma in vitro and in vivo.
Huang F; Ma B; Wang Y; Xiao R; Kong Y; Zhou X; Xia D
Cancer Biother Radiopharm; 2014 Dec; 29(10):403-11. PubMed ID: 25414976
[TBL] [Abstract][Full Text] [Related]
15. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.
Zhao L; Gu J; Dong A; Zhang Y; Zhong L; He L; Wang Y; Zhang J; Zhang Z; Huiwang J; Qian Q; Qian C; Liu X
Hum Gene Ther; 2005 Jul; 16(7):845-58. PubMed ID: 16000066
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y
J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452
[TBL] [Abstract][Full Text] [Related]
17. Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a trend in both cancer gene therapy and cancer virotherapy.
Liu XY; Li HG; Zhang KJ; Gu JF
Curr Pharm Biotechnol; 2012 Jul; 13(9):1761-7. PubMed ID: 21740358
[TBL] [Abstract][Full Text] [Related]
18. Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma.
Wang CJ; Xiao CW; You TG; Zheng YX; Gao W; Zhou ZQ; Chen J; Xue XB; Fan J; Zhang H
Mol Cancer; 2012 May; 11():31. PubMed ID: 22569271
[TBL] [Abstract][Full Text] [Related]
19. Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus.
Zhang KJ; Wang YG; Cao X; Zhong SY; Wei RC; Wu YM; Yue XT; Li GC; Liu XY
Hum Gene Ther; 2009 Aug; 20(8):818-30. PubMed ID: 19320563
[TBL] [Abstract][Full Text] [Related]
20. A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas.
Kwon OJ; Kim PH; Huyn S; Wu L; Kim M; Yun CO
Clin Cancer Res; 2010 Dec; 16(24):6071-82. PubMed ID: 21169258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]